<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04647539</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0626</org_study_id>
    <nct_id>NCT04647539</nct_id>
  </id_info>
  <brief_title>Emerging Invasive Fungal Infections in Critically Ill Patients</brief_title>
  <acronym>EIFI</acronym>
  <official_title>Emerging Invasive Fungal Infections in Critically Ill Patients: Epidemiological Trends, Clinical Features and Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Beside Candida and Aspergillus, emerging invasive fungal infections (EIFIs) are&#xD;
      increasing in intensive care setting and are associated with high morbidity and mortality.&#xD;
      However, data are scarce, particularly in ICU settings and for EIFIs other than mucormycosis.&#xD;
&#xD;
      Objectives: to describe epidemiological trends and clinical features of EIFIs in intensive&#xD;
      care units (ICU) and to assess their outcome.&#xD;
&#xD;
      Methods: All records of adult patients diagnosed with an EIFI in a medical ICU between 2006&#xD;
      and 2019 were analyzed retrospectively. In-ICU mortality was assessed, then factors&#xD;
      associated with mortality were identified. Survival at day-90 was calculated by the&#xD;
      Kaplan-Meier method.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2006</start_date>
  <completion_date type="Actual">November 23, 2020</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>at ICU admission</time_frame>
    <description>mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mucormycosis</measure>
    <time_frame>at ICU admission</time_frame>
    <description>Mucormycosis</description>
  </secondary_outcome>
  <enrollment type="Actual">26</enrollment>
  <condition>Fungal Infection</condition>
  <condition>ICU Acquired Weakness</condition>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      NC&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients majeurs hospitalisés en reanimation et présentant une infection fongique invasive&#xD;
        autre qu'une candidose ou une aspergilloses&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        - Adults (≥ 18 years old) with at least 1 positive culture for molds other than candida and&#xD;
        aspergillosis&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - Age &lt; 18, pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Romaric Larcher, MD, PharmD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Emergind invasive fungal infection</keyword>
  <keyword>mucormycosis</keyword>
  <keyword>ICU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

